Preparing the structured Flagship evidence library.
Flagship peptide evidence profile
These are deterministic research-intelligence signals, not clinical conclusions.
This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.
Semaglutide · PMID 40353578
Mean weight change at week 72 was -13.7% with semaglutide and -20.2% with tirzepatide.
Semaglutide · PMID 33667417
Mean body-weight change was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo.
Semaglutide · PMID 35441470
Participants previously receiving semaglutide regained 11.6 percentage points of lost weight by week 120.
Semaglutide · PMID 33567185
Mean body-weight change at week 68 was -14.9% with semaglutide versus -2.4% with placebo.
Semaglutide · PMID 36578889
The pooled mean difference in weight reduction was -11.85% in favor of semaglutide versus placebo.
Semaglutide · PMID 31031702
The review describes albumin-binding strategies used to prolong liraglutide and semaglutide action.